Related Experiment Video

Updated: May 3, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.0K

Src mediates ERK reactivation in gefitinib resistance in non-small cell lung cancer

Nobuaki Ochi1, Nagio Takigawa2, Daijiro Harada3

  • 1Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan; Department of General Internal Medicine 4, Kawasaki Hospital, Kawasaki Medical School, Okayama 700-8505, Japan.

Experimental Cell Research
|January 21, 2014
PubMed

Insights

EGFR-TKI resistance in lung cancer can be overcome by targeting Src. Dual inhibition of EGFR and Src restores gefitinib sensitivity, suggesting a new therapeutic strategy for non-small cell lung cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are crucial for treating EGFR-mutant non-small cell lung cancer (NSCLC).
  • Acquired resistance to EGFR-TKIs like gefitinib remains a significant clinical challenge.
  • Understanding novel resistance mechanisms is essential for developing effective treatment strategies.

Purpose of the Study:

  • To investigate the mechanisms underlying gefitinib resistance in EGFR-mutant NSCLC.
  • To establish and characterize a novel gefitinib-resistant cell line (PC9-GR).
  • To identify potential therapeutic targets for overcoming gefitinib resistance.

Main Methods:

  • Established a gefitinib-resistant NSCLC cell line (PC9-GR) from PC-9 cells.
  • Analyzed signaling pathways including EGFR, ERK, PI3K-Akt, and Src.
  • Utilized pharmacological inhibitors (U0126, LY294002) and siRNA for pathway inhibition.
  • Evaluated gefitinib resensitization in vitro and in vivo.

Main Results:

  • Gefitinib suppressed EGFR signaling, but ERK was reactivated in PC9-GR cells.
  • ERK inhibition, but not PI3K-Akt inhibition, restored gefitinib sensitivity.
  • Src phosphorylation was upregulated with ERK reactivation, but not causally linked.
  • Dual inhibition of EGFR and Src re-sensitized PC9-GR cells to gefitinib.

Conclusions:

  • Src-mediated ERK reactivation represents a novel gefitinib resistance mechanism in NSCLC.
  • Combined gefitinib and Src inhibitor therapy may overcome acquired resistance.
  • This dual-targeting strategy holds potential for improving NSCLC treatment outcomes.
Keywords:
EGFRERKGefitinibLung cancerResistanceSrc

More Related Videos

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

9.5K
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

7.6K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.3K
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal01:22

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
1.8K